Related Experiment Video

Updated: Apr 30, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.8K

Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease

Colin A Hutchison1, Anne Burmeister2, Stephen J Harding3

  • 1Hawke's Bay District Health Board, Hawke's Bay, New Zealand.

Mayo Clinic Proceedings
|May 7, 2014
PubMed

Insights

Elevated serum polyclonal free light chain (FLC) levels are a significant predictor of mortality in individuals with chronic kidney disease (CKD). This finding highlights FLC levels as a crucial biomarker for assessing risk in CKD patients.

Area of Science:

  • Nephrology
  • Clinical Biomarkers
  • Epidemiology

Background:

  • Chronic kidney disease (CKD) affects millions globally, with mortality remaining a significant concern.
  • Identifying reliable predictors of mortality in CKD is crucial for patient management and risk stratification.
  • Polyclonal free light chains (FLC) are increasingly recognized for their role in various kidney diseases.

Purpose of the Study:

  • To investigate the association between elevated serum polyclonal free light chain (FLC) levels and mortality risk in a cohort of patients with chronic kidney disease (CKD).
  • To determine if combined FLC (cFLC) levels serve as an independent predictor of all-cause mortality in non-dialysis CKD patients without monoclonal gammopathy.

Main Methods:

  • A cohort of 848 individuals with CKD, excluding those on renal replacement therapy or with monoclonal gammopathy, was recruited between 2006 and 2007.
  • Serum kappa and lambda FLC levels were measured to calculate combined FLC (cFLC) levels.
  • The cohort was followed prospectively for a median of 63 months, with Cox regression analysis used to identify mortality predictors.

Main Results:

  • High serum cFLC levels were identified as an independent risk factor for death (HR, 2.71; P<.001).
  • Other independent predictors of mortality included older age, South Asian ethnicity, pre-existing cardiovascular disease, and elevated high-sensitivity C-reactive protein.
  • Estimated glomerular filtration rate and albuminuria were not found to be independent risk factors for mortality in this cohort.

Conclusions:

  • Elevated serum polyclonal free light chain (FLC) levels independently predict mortality in individuals diagnosed with chronic kidney disease (CKD).
  • cFLC levels represent a valuable prognostic biomarker for assessing mortality risk in the CKD population.
  • These findings underscore the importance of monitoring FLC levels in CKD patients for improved risk stratification.
Abstract

More Related Videos

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.6K
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.8K

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
679
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.1K
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.4K
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
688
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
337
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.8K